Tag:

Celgene

Latest Headlines

Latest Headlines

Celgene's powerhouse Revlimid gets a little Q3 help from new friends Pomalyst, Otezla

Celgene's growth engine Revlimid came through again this quarter. The blood cancer drug's $1.3 billion in Q3 sales--a 19% increase--helped the company hit sales estimates and beat profit expectations. And if a new first-line indication wins FDA approval, expected soon, the drug could take another leap next year.

Celgene adds $1B-plus immuno-oncology deal, buyout option for Sutro

Close to two years after Celgene closed its first development deal with Sutro Biopharma, the prolific partnering machine at the big biotech has come back and taken an option on buying the company and its antibody-drug conjugates and bispecifics. And Celgene is expanding their collaboration to include immuno-oncology drugs, the hottest R&D field in biotech.

Celgene takes equity stake in Sequenta and its precise Dx tech

Sequenta attracted new equity investment from Celgene and other unnamed parties that back the use of its technology in the drug development process and the creation of new ultraprecise diagnostic tests.

Celgene's $2.6B deal for Crohn's drug pays off with promising PhII

Celgene bet big on the little-known Irish biotech Nogra Pharma when it partnered on a mid-stage drug for Crohn's disease. And today Celgene spelled out the reasons why it gambled $710 million upfront on a Phase II drug, highlighting data that support a clear case that the therapy can help spur clinical remission in a broad group of patients.

Déjà vu for Celgene as NICE says 'no' to myeloma drug Imnovid

The U.K.'s cost-effectiveness watchdog has recently sounded a bit like a broken record when it comes to its cancer drug rejections. The latest to get a "no-go" from the gatekeeper? Celgene's Imnovid.

Celgene's Otezla nabs psoriasis approval, launching next-gen showdown

Celgene's anti-inflammatory newcomer Otezla just took another step toward the powerhouse. The drug won FDA approval in a big market important to its sales: psoriasis, the most common autoimmune disease in the U.S. It's the first in a new generation of psoriasis meds to nab that indication.

NICE says 'too pricey' to Celgene's Abraxane combo for pancreatic cancer

The U.K.'s cost-effectiveness watchdogs are cracking down on expensive cancer treatments yet again. This time the ax is falling on Celgene, which learned today that the National Institute for Health and Care Excellence (NICE) won't back the company's drug Abraxane to treat metastatic pancreatic cancer.

Bristol-Myers, Celgene pair an immuno-oncology star with a rising chemotherapy

Bristol-Myers Squibb and Celgene are joining forces on a cancer combination treatment, testing the former's highly anticipated immunotherapy in tandem with an on-the-market chemo drug against a host of tumor targets.

Celgene's cost-sharing offer persuades NICE to about-face on Revlimid

Celgene used a tried-and-true technique to persuade cost-effectiveness watchdogs to change their minds on Revlimid. The U.S.-based drugmaker capped its cost.

Celgene cost-sharing deal sways NICE to greenlight new Revlimid use

Celgene used a tried-and-true technique to persuade cost-effectiveness watchdogs to change their minds on Revlimid. The U.S.-based drugmaker capped its cost.